<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02994446</url>
  </required_header>
  <id_info>
    <org_study_id>RD-14-001P</org_study_id>
    <nct_id>NCT02994446</nct_id>
  </id_info>
  <brief_title>Saline-Enhanced Radiofrequency (SERF) Catheter Ablation for the Treatment of Ventricular Tachycardia</brief_title>
  <acronym>SERF-VT</acronym>
  <official_title>Saline-Enhanced Radiofrequency (SERF) Catheter Ablation for the Treatment of Ventricular Tachycardia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thermedical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thermedical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the technical feasibility of the SERF Catheter
      and SERF Cardiac Ablation System to eliminate or control ventricular tachycardia (VT)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events that are potentially device-related</measure>
    <time_frame>Within 30 days of ablation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events</measure>
    <time_frame>Within 2 days after ablation procedure</time_frame>
    <description>MACE will be accessed from time of ablation to time of discharge from hospital following the ablation (generally within 2 days of ablation procedure).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-inducibility of clinical ventricular tachycardia (VT) and/or elimination of clinically relevant scar or channels</measure>
    <time_frame>At completion of ablation procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraprocedural non-inducibility and/or scar homogenization of target VT</measure>
    <time_frame>At completion of ablation procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination of the target VT and/or reduction in number of VT episodes</measure>
    <time_frame>Within first 6 months of ablation procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Tachycardia, Ventricular</condition>
  <arm_group>
    <arm_group_label>SERF Catheter Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Saline-Enhanced Radiofrequency Catheter and Ablation System</intervention_name>
    <description>Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter</description>
    <arm_group_label>SERF Catheter Ablation</arm_group_label>
    <other_name>SERF Ablation System and Durablate™ Ablation Catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ischemic post myocardial infarction ventricular tachycardia (VT)

          -  Scar identified on imaging

          -  Drug refractory or drug intolerant VT following use of at least one Class III
             antiarrhythmic as demonstrated by a recurrent arrhythmia and is not a suitable
             candidate per the investigator's expert opinion for ongoing or alternative drug
             therapy

          -  Prior failed ablation as evidenced by implantable cardioverter defibrillator device
             therapy within the prior 3 months

          -  Minimum 3 month implantable cardioverter defibrillator interrogation history available

          -  Left ventricular ejection fraction greater than or equal to 20%

          -  18-75 years old

          -  Signed informed consent and willing and able to participate in all study procedures
             and follow up requirements

        Exclusion Criteria:

          -  Patients without ischemic, scar-related VT

          -  VT with findings suggestive of right ventricular free wall origin findings

          -  VT of septal origin may be excluded. Patients requiring ablation at such locations
             should only be included when the arrhythmia itself is life-threatening or otherwise
             sufficiently severe to justify the risk.

          -  Myocardial infarction or unstable angina within previous 60 days

          -  Cardiac surgery or percutaneous coronary intervention within previous 60 days

          -  Patients with NYHA class IV heart failure

          -  Prosthetic cardiac valve(s), severe aortic stenosis or flail mitral valve

          -  Left ventricular assist device planned or required for the procedure

          -  Co-morbidities such that a patient has less than 1 year life expectancy

          -  Significant intracardiac and/or laminated thrombus prior to ablation procedure

          -  Thrombocytopenia or other coagulopathy

          -  Pregnancy

          -  Other acute illness or active systemic infection (unrelated to VT or its origin)

          -  Significant congenital anomaly heart disease

          -  Allergy or contraindications to the medications/agents used during a standard
             ablation/EP intervention.

          -  Concurrently enrolled in any other investigational drug or device study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas L. Packer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Atul Verma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southlake Regional Health Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherri Patterson, RN</last_name>
    <phone>905-895-4521</phone>
    <phone_ext>2149</phone_ext>
    <email>spatterson@southlakeregional.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y-2P6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherri Patterson, RN</last_name>
      <phone>905-895-4521</phone>
      <phone_ext>2149</phone_ext>
      <email>spatterson@southlakeregional.org</email>
    </contact>
    <investigator>
      <last_name>Atul Verma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute - Institut de Cardiologie de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Girard</last_name>
      <phone>514-376-3330</phone>
      <phone_ext>4058</phone_ext>
      <email>caroline.girard@icm-mhi.org</email>
    </contact>
    <investigator>
      <last_name>Katia Dyrda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Quebec Heart and Lung Institute - Institut universitaire de cardiologie et de pneumologie de Québec</name>
      <address>
        <city>Québec</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Sanchez</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>2689</phone_ext>
      <email>marina.sanchez.1@ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Isabelle Nault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2016</study_first_submitted>
  <study_first_submitted_qc>December 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2016</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

